Preprint Hypothesis Version 1 Preserved in Portico This version is not peer-reviewed

Could Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?

Version 1 : Received: 1 April 2020 / Approved: 2 April 2020 / Online: 2 April 2020 (11:28:57 CEST)
Version 2 : Received: 27 April 2020 / Approved: 27 April 2020 / Online: 27 April 2020 (09:55:03 CEST)

A peer-reviewed article of this Preprint also exists.


Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2 or SARS-CoV2) is the cause of the respiratory infection known as COVID-19. From an immunopathological standpoint, coronaviruses such as SARS-CoV2 induce an increase in a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines including interleukins IL-1, IL-6, CCL2 protein and CXCL10 protein. In the absence of proven antiviral agents or an effective vaccine, substances with immunomodulatory activity may be able to inhibit inflammatory and Th1 cytokines and/or yield an anti-inflammatory and/or Th2 immune response to counteract COVID-19 symptoms and severity. This report briefly describes four unconventional but commercially accessible immunomodulatory agents that could be employed in clinical trials to evaluate their effectiveness at alleviating disease symptoms and severity: Low-dose oral interferon-alpha, microdose DNA, low-dose thimerosal and phytocannabinoids.


COVID-19; SARS-CoV2, Immunomodulators


Biology and Life Sciences, Virology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.